Skip to main content

Clinical Trials – what CECOG offers

Clinical research is the key to develop new methods to prevent, detect and treat cancer. CECOG – as a non profit organization – has been conducting clinical trials for almost 25 years.

Our investigators are committed to conduct clinical trials in the prioritized fields of clinical cancer research including metastatic breast cancer, non-small cell lung cancer, metastatic colorectal cancer, gastroesophageal cancer, gastrointestinal stromal tumors (GIST), pancreatic and prostate cancers.

CECOG Services in Clinical Trials

CECOG provides full service for phase I-III clinical trials with particular expertise in Central and Southeastern Europe where CECOG has a broad net of contacts with academic centers and commands highest expertise for the implementation of clinical trials and rapid patient recruitment via these services:

  • Scientific advice and support
  • Close cooperation with partners
  • Involvement of international advisory board (optional)
  • Study feasibility assessment
  • Design and plan of clinical trials
  • Site selection
  • Clinical trial logistics
  • Submission to EC and MoH
  • Site monitoring
  • Project Management
  • Data Management, Biostatistics

Our Experience

We have been providing support for Pharma and Biotech industries for over 20 years.

In cooperation with dedicated local partners we can provide high quality performance at more than 150 academic sites in 23 countries. By following GCP-ICH guidelines, SOP´s and international and national regulations we deliver high quality results of clinical trial.

CECOG offers an extensive portfolio of services which can be customized to meet the individual needs of each client.

Quality Assurance

Quality control is the basic requirement for the conduct of clinical trials.

CECOG has proved to be a quality-oriented body with clearly defined decision lines acknowledged and certified by both, government inspections and industry-driven audits. All CECOG sites are subject to comonitorings. Thus, a smooth and correct conduct of each trial is guaranteed.

During the past years, CECOG successfully underwent the following inspections and audits:

 

  • Site Audit – GEICAM, June 2018
  • Site Audit – GEICAM, November 2018
  • Site Inspection Hungary – MoH, October 2017
  • Site Audit and CECOG office Audit – GEICAM, November 2016
  • Site Inspection Israel –MoH, September 2009
  • Site Inspection Serbia –MoH, September 2009
  • Site Inspection Romania – FDA, March 2009
  • Quality Assessment – Merck, November 2008
  • Site Audit and CECOG office audit – Eli Lilly, April 2007
  • Site Inspection – AGES (Austrian Health Authority), April 2006
  • Quality Assessment – Eli Lilly, January 2005
  • Audit – Novartis, November 2004
  • Quality Assessment – Eli Lilly, September 2004